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ABSTRACT
Pharmacokinetic variability in a population is the variability in plasma drug concentra-
tions among individuals. It may, for instance, be caused by differences in genes coding for
drug-transport proteins and metabolizing enzymes, amount of body fat, age, sex, patient
compliance, diet or disease progression. For anticancer agents, the combination of a high
variability and a narrow therapeutic window may cause adverse side events, with additional
suffering for already aﬄicted patients and with high costs for society.
The work in this thesis aims to explore the possibilities for individualized treatment of
two specific anticancer drugs, paclitaxel and imatinib, by developing mathematical models
to investigate their pharmacokinetic variability.
In Paper I, two existing population pharmacokinetic models for paclitaxel are compared
using a clinical study comprising thirty-three women treated for ovarian cancer. Using iden-
tifiability and sensitivity analysis, it is shown that a model describing the relation between
total, unbound, and bound drug can be used with at least as good fit as a more empirical
model, although only total plasma concentrations of paclitaxel are available.
In Paper II, the conclusions from Paper I are used to expand the mechanism-based model
for paclitaxel to also include three metabolites. It is shown that the solubilizer Cremophor
EL seems to have a strong effect on the kinetics of the two hydroxy-metabolites. Clearance
of the main metabolite 6α-hydroxypaclitaxel (fraction metabolized) was significantly corre-
lated (p < 0.05) with the ABCB1 allele G2677T/A. Individuals carrying the polymorphisms
G/A (n = 3) or G/G (n = 5) showed a 30% increase, whereas individuals with polymor-
phism T/T (n = 8) showed a 27% decrease relative to those with the polymorphism G/T
(n = 17).
In Paper III, a population pharmacokinetic model for imatinib is developed using data from
a clinical study including fifty men and women on long-term treatment for gastrointestinal
stromal tumour. It is shown that the pharmacokinetics is best described using a model
with time dependent apparent bioavailability and absorption rate, which are decreased by
approximately 30% and 50%, respectively, after three months of treatment. In addition,
apparent clearance of imatinib was associated with the size of the liver metastasis, and was
decreased by almost 4% for every 100 cm3 of liver metastasis.
In Paper IV a semi-physiologically based pharmacokinetic model for paclitaxel and its
metabolites is developed using existing models and data available in the literature. Sensi-
tivity analysis of hepatic uptake, metabolism and eﬄux of the substances predicts systemic
plasma concentrations of 6α-hydroxypaclitaxel to be sensitive to changes in the capacity of
the ABCB1 transporter.
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1 Introduction
Interindividual pharmacokinetic variability can be described as the variability in drug
plasma concentrations among individuals in a population. Since plasma concentra-
tions are easily accessible using a simple blood test, they are very important in order
do understand the exposure of the drug on the body. For very potent drugs, such
anticancer drugs, which often affect both healthy tissue and tumours, administrating
a proper dose is crucial. Many anticancer drugs have a narrow therapeutic window,
meaning that the difference is relatively small between an ineffective and a harmful
dose. At the same time anticancer drugs often have a high pharmacokinetic variabil-
ity, and plasma concentrations may vary 2-10-fold between patients [88].
The sources causing pharmacokinetic variability can be categorized as external
factors related to medical care, lifestyle or environment, and internal factors related
to individual biological characteristics. External factors may for instance comprise
diet, patient compliance and drug interactions from co-medications, while internal
factors include genetic differences in drug-transport and drug metabolizing systems,
amount of body fat, age-related hepatic blood flow, or hepatic dysfunction caused by
the disease [88].
1.1 Problem formulation
To minimize side effects from the treatment, adverse drug events (ADEs), the sources
causing pharmacokinetic variability need to be understood. Some adverse drug events,
such as hair loss and nausea, may be inevitable or can be handled using proper co-
medication. More serious adverse events, like severe neurotoxicity or bone marrow
suppression, may on the other hand make it necessary to interrupt the treatment.
Quantifying additional suffering from ADEs in individuals already carrying the
burden of a serious disease is difficult. Even if patients must be kept in focus, the
cost for society may be more easily estimated. A study in the United States by
Hassett et al. [31] investigated the various costs with respect to chemotherapy given
to women under age 64 suffering from breast cancer. It was estimated that only the
chemotherapy-related serious ADEs themselves were on average $1 271 per person and
year. It was also estimated that each year in the U.S. alone there are 35 000 women
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under age 64 suffering from breast cancer that receive chemotherapy and therefore
the total cost for these ADEs may reach $45 million per year. Stokes et al. [83]
evaluated the specific costs related to neutropenia (i.e., decreased count of the most
common type of white blood cell - neutrophils) in first-line chemotherapy treatment
of non-small cell lung cancer in patients aged 65 years or older in the U.S. For the
more serious form of neutropenia, aﬄicting almost 10% of the approximately 5 000
studied individuals, costs from ADEs were estimated to $2 700 per patient and month
[83].
Also in treatment using targeted anticancer drugs, which in contrast to chemother-
apeutic drugs are specifically aimed at the tumour cells, ADEs may be substantial
as recently reported by Borovicka et al. [7]. They estimated adverse dermatologic
toxicities in a small group of 130 patients to a median cost of $1 920 per patient.
Reported costs for ADEs may to some extent relate to different attitudes to preven-
tion and different skill levels at the clinics [71], or may not be directly attributable to
pharmacokinetic variability. However, because of the high additional costs for ADEs
also minor progress in individualized drug therapy based on reduced pharmacokinetic
variability could give significant savings, not to mention the prospect of fewer aﬄicted
patients.
In this thesis, internal factors potentially causing pharmacokinetic variability in
two anticancer drugs are investigated using modelling and analysis of mathematical
models.
1.2 Outline
The rest of the thesis is organized in the following way: Chapters 2 and 3 give the
medical and technical background to the work. Chapters 4 to 6 define the aims of
the thesis, describes the mathematical methods, patient material and software used.
In Chapter 7 the results from Papers I-IV are discussed, and Chapter 8 summarizes
the findings.
Note about bold text: To help the reader, several of the chapters or
sections start with a bold text section where the content of the section
is summarized. These sections do not contain any references and have
intentionally been written in a somewhat simplified language than what is
otherwise used. It is the wish of the author that the content of this thesis
is available to as large an audience as possible.
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2 Medical background
2.1 Paclitaxel
Paclitaxel is a naturally occurring substance that is derived from the tree
Pacific Yew. Together with the chemically closely related semi-synthetic
substance docetaxel it make up the taxane group of anticancer drugs. Pa-
clitaxel inhibit cell division by stiffening parts of the cell skeleton, and is
used in cancer treatment (chemotherapy) primarily against ovarian, breast
and non-small cell lung cancer. Like other chemotherapeutic drugs, pacli-
taxel do not specifically target tumour cells but may affect all cells, and
have an effect against cancer because tumour cells divide more rapidly
than normal cells.
2.1.1 The drug
The discovery of paclitaxel was due to a major survey, initiated by the U.S. Na-
tional Cancer Institute in the late 1950s, with the goal to identify naturally occurring
anti-cancer substances. Bark extract from the Pacific Yew (lat. Taxus brevifolia)
was found to have anti-tumour effect, and in 1971 paclitaxel was identified as the
underlying cytotoxic substance [70]. The actual mechanism was identified in 1979 as
stabilization of microtubules [74]. By binding to the protein β-tubulin, which together
with α-tubulin composes the microtubules, paclitaxel will promote stabilization of the
microtubules to a degree where they cannot disassemble at cell proliferation, with cell
death as result [70].
Figure 2.1 describes the metabolism of paclitaxel, which itself is the active sub-
stance. Hepatic metabolism of paclitaxel is a one- or two-step process involving
the cytochrome P450 enzyme family. Paclitaxel is first metabolized to the CYP2C8
product 6α-hydroxypaclitaxel [67], the main metabolite [29, 50], or the CYP3A4/3A5
product p-3’-hydroxypaclitaxel [30]. 6α-hydroxypaclitaxel and p-3’-hydroxypaclitaxel
can then be further metabolized to 6α-, p-3’-dihydroxypaclitaxel, by CYP3A4/3A5
or CYP2C8, respectively [82]. In vitro studies have estimated that approximately
60% of the first step of the liver metabolism of paclitaxel is via CYP2C8 [13]. Both
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paclitaxel and its three metabolites are mainly cleared via feces, with approximately
70% of the dose cleared by this route [91].
Figure 2.1: The metabolism of paclitaxel (PAC) in the liver to 6α-hydroxypaclitaxel (6α-
OH-PAC), p-3’-hydroxypaclitaxel (p-3’-OH-PAC) and 6α-, p-3’-dihydroxypaclitaxel (6α-,
p-3’-diOH-PAC). Squares represent substances and ellipses represent enzymes. The effect is
shown with a dashed arrow.
In vitro experiments have demonstrated that hepatocellular uptake of paclitaxel
is carried out by OATP1B3, a member of the membrane transport proteins known
as organic anion-transporting polypeptides (OATP) [80], while cellular eﬄux is fa-
cilitated by ABCB1 (P-glycoprotein/P-gp, mdr-1), a member of the ATP-binding
cassette [41].
Because paclitaxel plasma concentrations show a large interindividual variabil-
ity, several studies have investigated associations between pheno- and genotypes and
pharmacokinetics. Significant findings include gender, age, body weight, and biliru-
bin [36, 43]. The metabolizing enzymes and transport proteins described above have
also been the subject of investigation in several studies, [6, 27, 37, 59, 79, 97]. The
outcome of these studies are inconclusive; of the two largest studies Henningsson
et al. [37] found no associations for polymorphisms in CYP2C8, CYP3A4, CYP3A5
or ABCB1, while Bergmann et al. [6] reported CYP2C8*3 to be associated with 11%
lower clearance of paclitaxel.
2.1.2 Cremophor EL
Because of its poor solubility in water and biological fluids, such as plasma, paclitaxel
is commonly administrated in an equal mixture of the nonionic solubilizer Cremophor
EL R© (BASF Corp.), a castor oil derivative, and ethanol [21]. The trademark for
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this specific combination is Taxol R© (Bristol-Myers Squibb). Although many adverse
drug events from treatment with Taxol are attributable to paclitaxel, it has also
been shown that ADEs like hypersensitivity reactions may be caused by Cremophor
EL itself [21, 34]. Further, it has been shown that the solubilizer alters the pharma-
cokinetics of paclitaxel, since total plasma concentrations of paclitaxel typically follow
nonlinear (saturable) pharmacokinetics [23, 81] while unbound plasma concentrations
of paclitaxel follow linear pharmacokinetics [35, 36]. Notably, docetaxel, for which
another solubilizer than Cremophor EL is used, has also been described using linear
pharmacokinetics [8, 51].
2.1.3 Ovarian cancer
Ovarian cancer is a group of three different forms of cancer that all relate to the
ovaries. The most common one is epithelial ovarian cancer, which is estimated to
cover 90% of all cases of ovarian cancer, while stromal ovarian cancer and germ
cell ovarian cancer each account approximately equally for the remaining cases [2].
According to global statistics from 2008, ovarian cancer is the seventh most common
cancer-related death world-wide in the female population, with approximately 226 000
new cases annually, and 140 000 deaths [42]. It is estimated that 10% of all cases are
due to factors of inheritance, and of these do 90% relate to mutations in two specific
genes BRCA1 and BRCA2 [84], which are also related to breast cancer. Decreased
risk is associated with, e.g., pregnancy, breastfeeding and the use of birth control pills
[84].
Surgery is the most important method for diagnostics of ovarian cancer, and also
the primary approach for treatment of the disease. If tumours are found, the stage of
the disease is measured by the International Federation of Gynecology and Obstetrics
(FIGO) staging system. The FIGO system consists of four main stages (I-IV), where
stage I is the least serious, with tumour growth limited to the ovaries, and stage IV
is the most serious, with distant metastases. Because 75% of cases are diagnosed at
stage III or IV, diagnosis is often poor [63].
Postoperative treatment with chemotherapy is almost always recommended, with
a few exceptions [2, 55]. The standard treatment comprise a three-hour intravenous
infusion of paclitaxel 175 mg/m2 in combination with carboplatin, given every third
week for six cycles [84, 85]. If relapse occurs the patient may be re-treated using the
same or other drugs depending on her development of drug resistance. Although pa-
clitaxel is administrated in relation to the patients’ body-surface area, differences in
interindividual plasma concentrations are large. The risk for relapsing patients to de-
velop drug resistance and the fact that paclitaxel may cause serious ADEs emphasizes
the importance of individualized drug therapy.
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2.2 Imatinib
Imatinib can be considered to be the first developed anticancer drug that
was specifically designed to target certain kinds of tumour cells. By bind-
ing to and inhibiting a specific protein, it decreases the activity of tumour
cells and causes cell death. Originally developed for treatment of a par-
ticular type of leukemia, imatinib is now also used in treatment of gas-
trointestinal stromal tumour and other cancers that expresses the specific
protein.
2.2.1 The drug
Imatinib (imatinib mesylate, Gleevec, Glivec), was developed during the 90s as an
inhibitor for a specific type of tyrosine kinase, BCR-ABL, a fusion oncoprotein ex-
pressed in the malignant cells of chronic myeloid leukaemia [20]. Imatinib was also
found to inhibit the KIT tyrosine kinase, for which mutations are frequent in gas-
trointestinal stromal tumours [10, 12].
Imatinib has a bioavailability of 98% [61] and is mainly metabolized in the liver by
CYP3A4/3A5 to the active metabolite CGP 74588 [17]. The drug is mainly excreted
in feces (67%) and to a smaller amount in urine (13%) [28].
2.2.2 Gastrointestinal stromal tumour
Gastrointestinal stromal tumour (GIST) is believed to origin from the interstitial cells
of Cajal (ICC) [12], i.e., the cells that uses electrical signalling to stimulate the smooth
muscles in the gastrointestinal tract, causing the contraction essential for processing
of nutrients. An import characteristic and biomarker for GIST are specific mutations
in the KIT tyrosine kinase receptor. KIT-mutations are present in about 85% of
GISTs, while mutations in another tyrosine kinase receptor, the PDGFRA, is present
in about 5% [10] of cases. KIT is important since normal tissue usually contains an
equilibrium of non-active receptors and receptors activated by extracellular ligands
[12]. In most GIST, the tyrosine kinase receptors are activated without the ligands,
which results in further activation of signalling pathways and ultimately transcription
of oncogenes [12].
GIST usually origins in the stomach or the small intestine; 60% of cases, or in
the small intestine; 30% of cases [10]. Although distant metastasis occur, the tumour
usually only metastasize to nearby tissue, such as the liver. Based on data between
1983 and 2000, Nilsson et al. [60] estimated the annual incidence of GIST in Sweden
to 14.5 per million, while the prevalence was 129 per million for all GIST risk groups.
Before the inclusion of imatinib in treatment of GIST, conventional chemotherapy
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was used, usually with very poor response. Following the introduction of imatinib in
treatment of advanced GIST, the median survival time has increased from 18 months
to 5 years, where 34% of the patients survive more than 9 years [12].
The standard dosing scheme for imatinib in treatment of patients with advanced
GIST or relapsed patients, consists of a 400 mg oral dose daily, often with treatment
lasting at least one year [10]. Although the response rate to imatinib therapy is
affected by the primary oncogenic mutation in the tyrosine kinase receptors, adherence
is also important to keep disease control, and since secondary mutations often lead
to drug resistance [3, 12].
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"Nothing in life is to be feared,
it is only to be understood."
Marie Curie
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3 Technical background
3.1 Model building of dynamical systems
The description of the distribution of a drug in the body or the elimination
in the liver can often be approximated by a mathematical model, consisting
of time-depending equations called differential equations. Specifically, the
well-known Michaelis-Menten equation can be described in this setting.
It is commonly used to describe a concentration-dependent or saturated
process, for which an increase in drug concentration only will cause in-
creased enzymatic drug elimination up to a certain concentration limit,
after which the elimination will remain at the same rate.
3.1.1 Systems and models
Consider a system S, represented by the cloud-like shape in Figure 3.1, for which
the inner structure is more or less known. The understanding of the system can
be improved by studying its behaviour, i.e., by making observations or performing
measurements on parts of it. Such measurable information is called output signals. If
these are dependent on time, S is called a dynamical system and the output signals
will be denoted y(t) (from here on bold text indicates a vector or a possible vector).
Apart from measuring the output signals, it may be possible to directly affect the
system in a way such that its output signals changes. If this is the case the dynamical
system is said to also have one or more input signals, denoted u(t). In this setting,
the boundaries of the system can be described by its input and output signals.
The process of creating a modelM of S can be performed in many ways. It will
depend on a number of factors, for instance i) the prior knowledge about S, ii) the
possibilities to vary input signals, iii) the possibilities of measuring the output signals
and iv) the choice of modelling tools. Creating a model based on these features is
the subject of the area of system identification. For extensive reading see for instance
Ljung [53].
A common way to represent a model mathematically is with ordinary differential
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Figure 3.1: A dynamic system S with input u(t) and output y(t).
equations, which may be nonlinear. If the following formulation is used:
x˙(t) = f(x(t),u(t),θ) (3.1a)
y(t) = h(x(t),u(t),θ) (3.1b)
the model is said to be on state-space form. In (3.1), x(t) = (x1(t), . . . , xn(t))T (a
vector of n state-variables), x˙(t) = (x˙1(t), . . . , x˙n(t))T (the vector of corresponding
time derivatives), u(t) = (u1(t), . . . , um(t))T (a vector of m input signals), y(t) =
(y1(t), . . . , yp(t))
T (a vector of p output signals), θ = (θ1, . . . , θr)T (a vector of r
parameters) and f(·) = (f1(·), . . . , fn(·))T and h(·) = (h1(·), . . . , hp(·))T (vectors
of the respective functions). Since observations often are discrete it is sometimes
preferable to view the output signals as such as well. For this purpose a general
model will, instead of (3.1), be denoted:
x˙(t) = f(x(t),u(t),θ) (3.2a)
yj = h(xj,uj,θ) (3.2b)
where yj is the jth vector of output signals, measured at time tj, and xj = x(tj) and
uj = u(tj).
It is important to remember that any model of the system S is just a model.
This means that it will most likely never be possible to explain the behaviour of
the output information at all times, but perhaps only the main characteristics under
certain conditions.
3.1.2 Mass-action and Michaelis-Menten kinetics
The following example is a modified version of the example found in Edelstein-Keshet
[16]. Similar examples can also be found in most literature concerned with general
biochemistry [5] or enzyme kinetics [77].
Consider a drug molecule, denoted X1, in the body of a patient that is being
treated for some medical condition. Although the objective of the drug dosage is to
produce an improvement of the current condition of the patient, the drug is in most
cases still a foreign substance from a bodily perspective. Fractions of the drug dose will
therefore never reach its target within the body, but instead undergo detoxification
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in some organ, most commonly in the liver. The detoxification process is handled by
one or several classes of proteins acting as enzymes. Let the specific class of enzymes
being responsible for the elimination of the drug be denoted by X2. Assume that
each enzyme handles exactly one drug molecule at a time. The process may then be
described according to:
X1 +X2
k1−→X3 (3.3a)
X1 +X2
k−1←−X3 (3.3b)
X3
k2−→ X4 +X2 (3.3c)
where the drug-enzyme complex is denoted by X3, in (3.3a). The reaction can then
either be reversed forming X1 and X2 in (3.3b), or proceed so that the parent drug
molecule X1 is converted to its metabolite X4 that dissociate from the enzyme X2 in
(3.3c). k1, k−1 and k2 are the rate constants associated with the reactions in (3.3a)–
(3.3c) respectively. Instead of working with the singular molecules X1, X2, X3 and
X4 it may be preferable to work with the corresponding concentrations c1, c2, c3 and
c4. For, e.g c3, the law of mass action now implies that:
Rate of formation of c3 = k1c1c2 (3.4a)
Rate of break-down of c3 = −k−1c3 − k2c3 (3.4b)
Using mass action kinetics on all concentrations give the following system of differ-
ential equations:
c˙1(t) = −k1c1(t)c2(t) + k−1c3(t) (3.5a)
c˙2(t) = −k1c1(t)c2(t) + k−1c3(t) + k2c3(t) (3.5b)
c˙3(t) = k1c1(t)c2(t)− k−1c3(t)− k2c3(t) (3.5c)
c˙4(t) = k2c3(t) (3.5d)
where c˙i(t) denotes the time derivative of ci(t). Equations (3.5) are valid if it can
be assumed that no new enzymes are formed during the time for which the chemical
reactions are occurring. This implies that the time considered for the process should
be sufficiently small, but how small depends on the specific system. Adding (3.5b)
and (3.5c), gives:
c˙2(t) + c˙3(t) = 0 (3.6)
and it becomes apparent that the concentration Etot of all enzymes, both unoccupied
and occupied, is constant during the process:
c2(t) + c3(t) = Etot ⇔ c2(t) = Etot − c3(t) (3.7)
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(3.5) can now be reduced by inserting (3.7) in (3.5a) and (3.5c). Also, since none
of the equations in (3.5) depend on c4, (3.5d) does not need to be considered, which
gives:
c˙1(t) = −k1Etotc1(t) + (k−1 + k1c1)c3(t) (3.8a)
c˙3(t) = k1Etotc1(t)− (k−1 + k2 + k1c1(t))c3(t) (3.8b)
If no further assumptions regarding the system should be done, equations (3.8) will
be the final model. However, reduction to a simpler model is possible with the quasi-
steady-state assumption, which will provide the Michaelis-Menten equation.
A common property for enzymatic systems such as (3.8) is that the equilibrium of
c3(t) is attained a lot faster than that of c1(t). Thus, under such specific circumstances
it can be allowed to assume quasi-steady-state and set:
c˙3(t) ≈ 0 (3.9)
Then, solving (3.8b) for c3 yields:
c3(t) =
k1Etotc1(t)
k−1 + k2 + k1c1(t)
(3.10)
This expression can be inserted into (3.8a), which then simplifies to:
c˙1(t) = − Vmaxc1(t)
KM + c1(t)
(3.11)
where
Vmax = k2Etot (3.12)
and
KM =
k−1 + k2
k1
(3.13)
(3.11) is the Michaelis-Menten equation and Vmax is the maximal reaction rate that
occurs when the concentration of occupied enzymes equals the total concentration
of enzymes. KM is usually called the Michaelis constant, and is equal to the drug
concentration at which the reaction rate is half of Vmax.
3.2 Pharmacokinetics
Pharmacokinetic modelling basically means trying to build a model of
what the body does with the drug. Mechanisms related to absorption,
distribution and elimination of the drug are studied. This is in contrast to
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pharmacodynamic modelling, where the focus is what the drug does with
the body, or simply the effect of the drug. Both types of modelling often
includes the use of differential equations to describe drug concentrations
or drug effects.
3.2.1 Compartment models
Depending on the administration, distribution and elimination characteristics of a
drug, measured plasma concentrations as function of time will give rise to different
curvatures. To be able to model the decrease in drug concentration in plasma, the
body is usually considered to consist of one or more compartments. Since they cannot
in general be related to any kind of physiological compartments, these compartments
should be considered to be empirical [33, 68].
If a drug is administrated as, e.g., an intravenous injection the absorption phase
does not need to be considered. In that case, the number of compartments that
are used to fit the measured concentrations will be equal to the degree of a multi-
exponential function. If interpolation of measured plasma concentrations cause a plot
like the one in Figure 3.2, a one compartment model with linear elimination may be
sufficient to model the pharmacokinetics. The mathematical representation will then
simply be a mono-exponential function:
cp(t) = c0e
−k10t (3.14)
where c0 is the initial drug concentration and k10 (also commonly denoted kel) is the
rate at which the drug is being eliminated. Graphically, this model can be represented
by Figure 3.3.
Since the drug dose is given as a specific amount, and not as a concentration based
on the distribution volume, it may be convenient to rewrite (3.14) on state-space form
and symbolically also adding an input signal:
x˙(t) = −k10x(t) + u(t) (3.15a)
cp(t) =
1
V
x(t) (3.15b)
where the state-variable x(t) is the amount in mol and the input signal u(t) is some
function corresponding to the dose input. V is the apparent volume of the single
compartment and can in this case be considered to be the same as the volume of
distribution Vd.
Another example of a typical decrease of the drug concentration in plasma as a
function of time is given in Figure 3.4. In this case taking the logarithm reveals that
two compartments should be used in the pharmacokinetic model. The mathematical
13
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Figure 3.2: Left: The decrease in plasma concentration after a bolus dose. Right: By taking
the logarithm of the plasma concentrations it becomes apparent that a one-compartment
model may be used.
Figure 3.3: The graphical representation of (3.14).
model then becomes:
x˙1(t) = −(k10 + k12)x1(t) + k21x2(t) + u(t) (3.16a)
x˙2(t) = k12x1(t)− k21x2(t) (3.16b)
cp(t) =
1
V1
x1(t) (3.16c)
where k12 and k21 are rate constants and V1 is the apparent distribution volume of
compartment one. Its corresponding graphical representation is seen in Figure 3.5.
Instead of using rate constants (ormicro constants) such as k10, k12 and k21, a parame-
ter, Q, representing the intercompartmental volume flow, clearance CL, and apparent
volumes V1 and V2, for each respective compartments may be preferred. Hence, using
the reparameterization:
k10 =
CL
V1
, k12 =
Q
V1
, k21 =
Q
V2
(3.17)
(3.16) can be expressed as:
x˙1(t) = −CL
V1
x1(t)− Q
V1
(x1(t)− x2(t)) + 1
V1
u(t) (3.18a)
x˙2(t) =
Q
V2
(x1(t)− x2(t)) (3.18b)
cp(t) =
1
V1
x1(t) (3.18c)
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Figure 3.4: Left: A second example of a typical decrease in plasma concentration after a
bolus dose. Right: Taking the logarithm of the plasma concentration reveals that a two-
compartment model may be used.
Figure 3.5: The graphical representation of (3.16).
Finally, an example is given in Figure 3.6 in the case when the drug elimination
does not seem to be linear for logarithmic plasma concentrations. In the right plot
it can be seen how the elimination appears to be slower during the initial period of
time than at the end. This behaviour is typical for a capacity limited elimination
process. In the beginning the system is saturated and elimination is independent of
concentration. First after plasma concentrations have been reduced to a certain level
will the elimination appear to be linear. By replacing −k10x(t) in (3.15a) with (3.11),
an appropriate model for this process can be expressed as:
x˙(t) = − Vmax
x(t)
V
KM +
x(t)
V
+ u(t) (3.19a)
cp(t) =
1
V
x(t) (3.19b)
where the concentration c(t) in (3.11) has been replaced by the amount x(t) scaled
by the volume V .
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Figure 3.6: Left: A third example of a typical decrease in plasma concentration after a
bolus dose. Right: The logarithmic plot indicates a saturated elimination process.
3.2.2 Population pharmacokinetics
Clinical studies may often be categorized according to sparse or rich sampling. Sparse
data sets consist of only a few observations per individual, while rich data sets consist
of perhaps eight or more observations; however, there does not seem to be any strict
definitions. Also when working with a rich data set, building a specific model one at
a time based only on the observations for one individual will in many cases not be
practical. In the case of model (3.18) there are four parameters to estimate. With
perhaps only ten observations, there may be many sets of parameter estimates that
will fit the data.
The issue can be handled in the model building procedure by considering that
data from all individuals will be used simultaneously. By assuming a common model
structure for all individuals, and letting some or all parameters belong to a statistical
distribution, parameters can be estimated from the complete data set. This approach
is called population pharmacokinetics (PPK) and use the framework of nonlinear
mixed effects modelling [4]. In general, this can be seen as an extension of (3.2):
x˙i(t) = f(xi(t),ui(t),φi) (3.20a)
yij = h(xij,uij,φi) + εij (3.20b)
φi = g(zi,θ) + ηi (3.20c)
where each individual i will have its own structural model ; (3.20a) and (3.20b), and
where the subscript j refers to the jth observation for that individual. φi is the vector
of individual specific parameter values and εij is the residual error (or intraindividual
variability), which is assumed to belong to a normal distribution with mean zero and
covariance matrix Σ. The relation between φi and the vector of typical parameter
values for the population, θ, and the vector of covariates, zi, is governed by g(·) in the
parameter model (3.20c). Differences between φi and g(·) that cannot be explained by
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any covariates, will be accounted for by the interindividual variability (IIV) term ηi,
which is assumed to belong to a normal distribution with zero mean and covariance
matrix Ω. Both the residual error, εij, and the IIV, ηi, can enter the model in
different ways, such as additively as in (3.20), proportionally or exponentially.
Extending the model (3.18) to a PPK model could mean using an IIV exponen-
tially on the parameter CL, while also assuming a proportional residual error:
x˙1,i(t) = −CLe
ηi
V1
x1,i(t)− Q
V1
(x1,i(t)− x2,i(t)) + 1
V1
ui(t) (3.21a)
x˙2,i(t) =
Q
V2
(x1,i(t)− x2,i(t)) (3.21b)
cp,ij =
1
V1
x1,ij(1 + εij) (3.21c)
In addition to the residual error and the IIV, other forms of variability can also be
included, such as interoccasion variability (IOV), which is important to consider in
the case of having multiple study occasions from the same individual in the data set
[48]. A further extension of (3.20) to stochastic differential equations has also been
made, [86, 87], where the approach is to separate the residual error to measurement
error and system noise using the extended Kalman filter [46, 87].
3.3 Identifiability
When estimating model parameters from data it may be a good idea to
investigate the identifiability of the model, meaning if it is possible to
obtain unique solutions for the parameter estimates. The identifiability
concept can be separated into structural identifiability, which relates only
to the model structure, independently of data, and practical identifiability,
which relates to combination of the model structure and the data set.
3.3.1 Structural identifiability
Structural identifiability can be understood by considering a modified version of the
one-compartment model (3.15). Assume that (3.15) is fitted to plasma concentrations
for a specific drug. However, also assume that it is known that the drug elimination
process is governed by two independent elimination mechanisms, A and B, each with
its own corresponding rate constant. Hence it would be desirable to incorporate
this knowledge into the model. Graphically this can be viewed as an alteration of
Figure 3.2 to Figure 3.7. By also expressing the model mathematically as:
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Figure 3.7: A one compartment model with two separate elimination mechanisms A and
B, and their respective rate constants kA10 and kB10.
x˙(t) = −(kA10 + kB10)x(t) + u(t) (3.22a)
cp(t) =
1
V
x(t) (3.22b)
it becomes apparent that the two rate constants in the current model setting are
indistinguishable. Only the sum kA10 + kB10 can be estimated, regardless if the output
signal cp(t) is considered to be "perfect", i.e., a continuous signal without any noise.
Thus, for this kind of identifiability problem it is the structure of the model rather
than the data that causes the problem. For the case of (3.22) one will simply have to
be satisfied with estimating the sum of the two parameters, at least unless some kind
of prior knowledge can be incorporated in another way, e.g., an approximate value of
either kA10 or kB10 is known.
In this work a model is considered to be globally structural identifiable if a unique
solution to the estimation problem exists without any restrictions on the parameter
space, and locally structurally identifiable if a unique solution to the estimation prob-
lem exists, at least within a small region of the parameter space. For instance, the
model:
x˙(t) = −(k10)2x(t) + u(t) (3.23a)
cp(t) =
1
V
x(t) (3.23b)
is not identifiable without any restrictions on k10, since only (k10)2 can be estimated
uniquely, which could mean both −k10 and k10 are valid solutions. But if only pos-
itive estimates k10 > 0 are considered the parameter, and hence the model, will be
identifiable. The model is locally structural identifiable since a unique solution exists
if the parameter space is restricted to all positive real numbers.
Further, the output signal is considered to be continuous, noise free and it is also
assumed that no excitation problems of the system exist or any numerical problems
during the estimation process [11]. Moreover, the identifiability properties of a model
are only valid for a specific state-space form, since reparameterization or removal of
output signals may change the structural identifiability. For a more formal definition
of identifiability see, e.g., Ljung [53].
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3.3.2 Practical identifiability
Even if a model is proved to be structural identifiable the data to which the model
is to be fitted may be too sparse to get reliable estimates. In this case the model
is overparameterized for the data at hand. Another problem could be if the data
does not excite the model in the right way. Assume for instance that prior knowledge
suggests the use of a one-compartment model with saturated elimination such as
(3.19) for concentrations of a specific drug measured in plasma. However, if the
current study uses a much lower drug dosage with the outcome that:
cp(t) =
1
V
x(t) << KM (3.24)
the model (3.19) will during the estimation process behave approximately as:
x˙(t) ≈ −Vmax
KM
x(t)
V
+ u(t) (3.25a)
cp(t) =
1
V
x(t) (3.25b)
From this perspective Vmax and KM will be indistinguishable and large variances
will most likely accompany the parameter estimates, if the minimization is at all
successful. This is an example of practical (non-)identifiability. The simplest solution
to the problem would be to use a one-compartment model with linear elimination
such as (3.15), in which case the rate constant k10 will correspond to the quota of
Vmax and KM , divided by V. Similar examples as the one presented and how to handle
these are discussed by Cedersund [11].
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4 Aims
The overall aim of the thesis is to explore the possibilities for individual-
ized treatment of two specific anticancer drugs, by developing models to
investigate their pharmacokinetic variability.
Specific aims
• To compare two pharmacokinetic models for paclitaxel and investigate if the
mechanistically more plausible model can be used even if limitations in data
will cause identifiability problems.
• To investigate the influence of the drug solubilzer Cremophor EL on paclitaxel
metabolite kinetics and to investigate correlations of clearance of paclitaxel and
its metabolites with enzyme activity and genetic polymorphisms.
• To develop a population pharmacokinetic model for imatinib and to investigate
correlations between pharmacokinetics and liver metastasis.
• To develop a semi-physiologically based pharmacokinetic model describing the
uptake, metabolism and eﬄux of paclitaxel and its metabolites and investigate
the effect of potential genetic polymorphisms.
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5 Methods
Several different methods may be used during model building, which is
often a loop-like process including parameter estimation from data, testing
identifiability and sensitivity of model parameters, and validating model
performance.
5.1 Nonlinear mixed effects models - Papers I, II & III
Parameter estimation of the population pharmacokinetic models presented in Section
3.2.2 is conducted by the framework of nonlinear mixed effects models. Because
it is assumed that any variability entering the model has its origin from a known
distribution, in particular a normal distribution, likelihood-based methods can be used
for estimation. It is also assumed that each individual i has its own statistical model,
which is based on all the observation data yi = (yi1, . . . , yiM)T for that individual.
Each model can be said to be parameterized by an individual specific vector ηi,
which is an instance of a normal distribution with mean zero and covariance matrix
Ω (the IIV, see Section 3.2.2), by the vector θ of population median values, and of
the residual covariance matrix Σ. The goal is hence to estimate θ, Σ and Ω from
all data sets yi, i = 1, . . . , N , where N is the number of individuals. For individual
i the probability of the data set yi given θ, Σ and Ω will thus be P (yi|θ,Σ,Ω), or
Li(θ,Σ,Ω|yi), which is the individual contribution to the population likelihood L.
Considering the expressions to be marginal distributions over ηi, gives:
P (yi|θ,Σ,Ω) = Li(θ,Σ,Ω|yi) =
∫
P (yi,ηi|θ,Σ,Ω)dηi
=
∫
P (yi|ηi,θ,Σ,Ω)P (ηi|θ,Σ,Ω)dηi
=
∫
P (yi|ηi,θ,Σ)P (ηi|Ω)dηi
=
∫
li(ηi,θ,Σ|yi)pη(ηi|Ω)dηi (5.1)
where li(ηi,θ,Σ|yi) is the individual likelihood function associated with the struc-
tural model (3.20a)-(3.20b), and pη(ηi|Ω) is the density function associated with the
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parameter model (3.20c). The second equality from the end in (5.1) follows from yi
not being explicitly dependent on Ω if ηi is given, and ηi not being dependent on θ
or Σ. Further, the population likelihood L for the complete data set Y is given by:
L(θ,Σ,Ω|Y) =
N∏
i=1
Li(θ,Σ,Ω|yi) (5.2)
and taking −2 log of (5.2) gives:
−2 logL(θ,Σ,Ω|Y) =
N∑
i=1
[−2 logLi(θ,Σ,Ω|yi)]
=
N∑
i=1
[
−2 log
∫
li(ηi,θ,Σ|yi)pη(ηi|Ω)dηi
]
(5.3)
5.1.1 First-Order Conditional Estimation in NONMEM
Because the integral in (5.3) is difficult to calculate exactly, different approximations
are often used. In NONMEM (Materials chapter, Section 6.2.1) several methods are
available that approximates (5.3); let:
Φi(ηi) = −2 log li(ηi,θ,Σ|yi) (5.4)
and denote its gradient vector ∇Φi(ηi), and the hessian matrix ∆Φi(ηi). If Laplace’s
method for approximation of integrals is used it can then be shown that an approxi-
mation for −2 logLi(θ,Σ,Ω|yi) in (5.3) is given by:
Φˆi + log |Ω|+ ηˆTi Ω−1ηˆi + log
∣∣∣∣Ω−1 + 12∆ˆΦi
∣∣∣∣
−
(
1
2
∇ˆΦi +Ω−1ηˆi
)T (
Ω−1 +
1
2
∆ˆΦi
)−1(
1
2
∇ˆΦi +Ω−1ηˆi
)
(5.5)
where ηˆi is some estimate of ηi, and Φˆi, ∇ˆΦi and ∆ˆΦi are the respective functions
evaluated at ηˆi [4]. If ηˆi is the mode obtained by maximizing the joint likelihood
li(ηi,θ,Σ|yi)pη(ηi|Ω)dηi, over ηi, the last term in (5.5) will vanish (compare with
the first-order derivative of a function optimum). Further, the Hessian, ∆Φi(ηi), can
be approximated by using first-order derivatives:
∆Φi(ηi) ≈
1
2
E
(∇Φi(ηi)∇Φi(ηi)T ) (5.6)
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where E is the expectation over yi for each individual structural model (3.20a)-(3.20b)
[92]. Inserting (5.6) in (5.5), while omitting the last term, gives:
Φˆi + log |Ω|+ ηˆTi Ω−1ηˆi + log
∣∣∣∣Ω−1 + 14E (∇Φi(ηi)∇Φi(ηi)T )
∣∣∣∣
ηˆi
(5.7)
where the bracket subscript, |ηˆi , denotes that ηˆi will be inserted after the expectation
over yi has been evaluated. The NONMEM method described in (5.7) is the First-
Order Conditional Estimation (FOCE) method, and can in turn be approximated
in several ways. For more information about the methods in NONMEM see the
NONMEM User’s Guides [4] and the derivations by Wang [92].
5.1.2 Objective Function Value and Akaike Information Cri-
terion
Similar to the other estimation methods in NONMEM, the FOCE is used to calculate
the Objective Function Value (OFV), which is hence proportional to −2× log likeli-
hood of the data. For two nested models, the OFV can be used directly for model
comparison because a difference in OFV, ∆OFV, is approximatively χ2-distributed
and can hence be used to perform a likelihood ratio test [4]. For instance, an addi-
tional parameter resulting in ∆OFV < −3.84 will thus be significant for p < 0.05.
For non-nested models, the OFV can still be used in model comparison by applying
the Akaike Information Criterion (AIC). AIC is expressed as:
AIC = OFV + 2h (5.8)
where h is the number of all parameters, both θs, ω2s and σ2s, that are estimated by
NONMEM, while fixed parameters are not considered. Similar to ∆OFV, the differ-
ence in AIC between two models, ∆AIC, can then be used to select the best model.
A rough rule of thumb has been suggested by Burnham and Anderson [9], where the
level of empirical support for an alternative model is suggested to be "substantial"
for ∆AIC = [0, 2], "considerably less" for ∆AIC = [4, 7], and "essentially none" for
∆AIC > 10. For the theory and derivation of the AIC, see for instance Ljung [53].
5.2 Local algebraic observability test - Paper I
Investigating structural identifiability can be seen as a special case of the more general
observability problem, which is concerned with determining whether a state-variable
is observable from input and output signals. By considering a parameter θ to be a
state-variable for which θ˙ = 0, structural identifiability can be investigated using the
framework of observability. A measure of the complete dynamics of a model given on
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state-space form (3.1) with a single output y, n state-variables and r parameters can
be described by the matrix O:
O =

∂y
∂x1
. . . ∂y
∂xn
∂y
∂θ1
. . . ∂y
∂θr
∂y˙
∂x1
. . . ∂y˙
∂xn
∂y˙
∂θ1
. . . ∂y˙
∂θr
...
...
...
...
∂y(n+r)
∂x1
. . . ∂y
(n+r)
∂xn
∂y(n+r)
∂θ1
. . . ∂y
(n+r)
∂θr

(5.9)
If the matrix is of full rank n+ r the model is structural identifiable [76]. If however
the rank test reveals that some columns are linearly dependent the model suffers from
overparameterization. To determine which parameters that are non-identifiable, one
column can be removed at a time and the effect on the rank of O can be checked. No
change indicates that the particular column removed corresponds to a non-identifiable
parameter. The number of columns that has to be removed for O to obtain full
rank is called its transcendence degree, and an identifiable model will thus have a
transcendence degree of zero [11, 76].
The symbolic derivations of the functions used in the matrix elements in (5.9) can
rapidly become quite cumbersome and acquire much computational time depending
on the size of the model. Sedoglavic [76] has presented an algorithm that bypasses
this problem by instead of calculating exact expressions uses Taylor approximations.
By using this approach and some other techniques the computations can be made
in polynomial time, i.e., the number of steps required to solve the algorithm will
be polynomial with respect to the complexity. It is a probabilistic algorithm in the
aspect that only if the model is observable the answer is for certain correct, while there
is a small possibility of an incorrect answer in the case of a non-observable model.
However, the probability of a correct answer in this case is very high. An example
presented by Sedoglavic [76], which comprises a model where the number of state-
variables n = 4 and the number of parameters r = 17, is shown to be non-observable
with a probability of 0.9993.
5.3 Frequentist priors - Paper II
For population pharmacokinetic models a special kind of method for handling identi-
fiability problems has been developed. It relies on the use of prior information in the
form of estimates of parameters and variances from earlier developed models. The
information is incorporated into the current model so as to mimic the resemblance if
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the data from the earlier study was also available. This approach will thus stabilize
any estimates with respect to such informative priors [22] or frequentist priors [24].
Reserving the use of OFV to numerical values, and instead denote the NONMEM
objective function OF, the terminology in Section 5.1 can be used to express the OF
as:
OF ∝ −2 logL =
N∑
i=1
[−2 logLi] (5.10)
Further, let OFi denote the individual contributions to the objective function OF, so
that:
OF =
N∑
i=1
OFi (5.11)
where the individual contributions could be summarized partially, making up two
contributions, e.g., OFA and OFB:
OF =
k∑
i=1
OFi +
N∑
i=k+1
OFi = OFA + OFB (5.12)
In essence, the OF will be defined by the data set Y , and the model structure under
consideration, M. Hence, the OF can be regarded as a function, OF(Y ,M). The
total OF can then be described as:
OF(Y ,M) = OFA(Y1,k,M) + OFB(Yk+1,N ,M) (5.13)
Now assume that only the data for the first k individuals, Y1,k, are available for model
building. Also assume that the data for the remaining individuals, Yk+1,N , have been
used previously to estimate parameters for the model structure M, and that the
model M(Yk+1,N) is available, including parameter estimates and standard errors.
Although the data set Yk+1,N is not directly available, its representation in terms of
the model M(Yk+1,N) is. To describe the total OF, the aim will thus be to find a
function OFP so that:
OFP (M(Yk+1,N)) ≈ OFB(Yk+1,N ,M) (5.14)
If the vectors of geometric means θ = (θ1, θ2, ...) (i.e., the typical population values)
and geometric variances ω2 = ((ω1)
2, (ω2)
2, ...) (i.e., the interindividual variability)
estimated fromM(Yk+1,N) can be considered independent, the joint density function
of a normal distribution and inverse-Wishart distribution, with ν degrees of freedom,
can be used as the function OFP . This is the Normal-inverseWishart Prior, described
by Gisleskog et al. [24], where the Normal corresponds to the multivariate normal
distribution of θ, and the inverse-Wishart corresponds to the distribution of the di-
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agonal matrix Ω comprising the elements of ω2. OFP will work as a penalty function,
since the sum OFA+OFP will be at minimum if the new estimates based on the data
set Y1,k and the previous estimates, θ and ω2, resemble each other. In NONMEM,
the required information for this approach are the priors of θ and ω2, including their
standard errors. The number of degrees of freedom ν for each ω2, may then be derived
from the respective standard error SEω2 of the variance ω2:
SEω2 = ω
2 ·
√
2
ν − 1 ⇒ ν =
2 · (ω2)2
(SEω2)
2 + 1 (5.15)
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6 Materials
6.1 Patient material
Two different studies were used in the thesis work, the first one included
thirty-three women receiving paclitaxel treatment for ovarian cancer, and
the second one included fifty patients receiving imatinib treatment for gas-
trointestinal stromal tumour. The two studies differ in a number of ways;
in the paclitaxel study only one series of measurements were performed
for each patient, while the patients in the imatinib study had about three
series of measurements each, with several months apart. In the pacli-
taxel study patients received their medication from a three-hour infusion,
and in the imatinib study each patient should themselves take his or her
medication each day for more than a year.
6.1.1 Paclitaxel study - Papers I & II
The main objective of the paclitaxel study was to investigate the role of the genetic
polymorphisms in the metabolizing enzymes CYP2C8 and CYP3A4, and the mem-
brane transport protein ABCB1 (P-gp, mdr-1) in the pharmacokinetics of paclitaxel.
The study comprised thirty-three women, aged 36 to 75 years (median 62), with dif-
ferent types of gynaecological cancers: epithelial ovarian cancer (n = 26), peritoneal
cancer (n = 4), ovarian or peritoneal (n = 1), carcinoma in corpus uteri (n = 1) and
in cervix uteri (n = 1) as described by Green et al. [27]. The subjects received an
intravenous infusion of paclitaxel (Taxol) for three hours, at 175 mg/m2 (n = 30)
or 135 mg/m2 (n = 3, due to poor general condition) and carboplatin. Thirty-one
subjects received at least six cycles of chemotherapy. One subject received only one
cycle due to septicaemia and another subject was withdrawn after four cycles due to
neurotoxicity.
Blood samples for pharmacokinetic analysis were collected during one cycle per
subject, between the first and eighth cycle (median cycle number 3), and collected
in EDTA tubes. The target times for sampling were; immediately before start of
infusion, at 30 min and 1 h after start, immediately before stop of infusion, at 5,
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15, 30 min and 1, 2, 4, 8 and 24 h after stop. Total concentrations of paclitaxel,
6α-hydroxypaclitaxel and p-3’-hydroxypaclitaxel were analyzed in samples from all
subjects, while 6α-, p-3’-dihydroxypaclitaxel, was analyzed in samples from fifteen
subjects. Samples were analyzed using solid phase extraction, reverse-phase high-
performance liquid chromatography and an ion trap mass spectrometer with a sonic
spray ionization interphase as described by Green et al. [26]. The number of samples
used in data analysis is presented in Table 6.1.
Enzyme activity for CYP3A4 in vivo could be determined in thirty-one subjects by
quinine administration prior to start of chemotherapy, as described by Mirghani et al.
[57, 58]. Genetic polymorphisms in CYP2C8, CYP3A4 and ABCB1 were determined
in all subjects using Pyrosequencing according to the protocol of the manufacturer
and as previously described [25, 27].
Table 6.1: Pharmacokinetic (PK) data for the paclitaxel study (n = 33)
PK samples Considered Missing (BQLb) Excludedc Used
Paclitaxel 352 2 (0) 5 345
6α-hydroxypaclitaxel 352 16 (12) 4 332
p-3’-hydroxypaclitaxel 352 13 (9) 3 336
6α-, p-3’-dihydroxypaclitaxela 164 18 (6) 3 143
Total 1220 49 (27) 15 1156
aFifteen subjects contributed with 6α-, p-3’-dihydroxypaclitaxel samples
bSome of the missing samples were possibly below quantification limit (BQL)
cRemoved because of a large (> 30%) within-sample variability in one subject
6.1.2 Imatinib study - Paper III
The objectives of the imatinib study were to develop a population pharmacokinetic
model based on long-term imatinib treatment, and to investigate correlations be-
tween pharmacokinetics and liver metastasis. Fifty subjects (29 males, 21 females)
diagnosed with gastrointestinal stromal tumour (GIST) were included in the study
at the start of treatment, in two Dutch and two Italian medical centers. Patients
already receiving drugs known to interact with the primary metabolizing enzyme(s)
CYP3A4/3A5 were not included in the study, if no alternative medication was avail-
able.
Blood samples for pharmacokinetic analysis (rich occasions) were collected on
the first day (Day 1) of imatinib treatment and mainly after 1, 6 and 12 months, see
Table 6.2. During the rich occasions, blood samples were collected immediately before
imatinib administration and 30 minutes, 1, 2, 3, 4, 6 and 24 hours after dose intake.
In addition, on day 14, and monthly during the treatment, trough samples were taken
immediately before the daily dose intake. Methods for blood sampling, storage, and
sample analysis were conducted as previously described by Schiavon et al. [73].
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Table 6.2: Number of rich occasions for each group of months for all fifty subjects
Months Day 1 1a, 2 and 3 5 and 6b 11c, 12c, 13, 14, 17, 18 and 22 Total
Occasions 50 49 45 45 189
a Month 1 contained 46 rich occasions
b Month 6 contained 40 rich occasions
c Months 11 and 12 contained together 37 rich occasions
Twenty-six subjects (13 males, 13 females) had liver metastasis. The volumes of
liver metastasis and liver were assessed by Computed tomography (CT), at start of
treatment, and after 6 and 12 months. Subjects not having liver metastasis were as-
signed a liver metastasis volume equal to zero, and hence also had a metastasis/liver
volume ratio of zero. Imatinib observations lacking information on volume of liver
metastasis and metastasis/liver volume ratio that belonged to subjects with metasta-
sis were excluded, leaving 1363 imatinib observations (the covariate data set) of the
1743 observations (the full data set) that were eligible for data analysis. The number
of samples used in data analysis is presented in Table 6.3.
Table 6.3: Pharmacokinetic (PK) data for the imatinib study (n = 50)
PK samples Considered Missinga Excludedb Used
Full data set 1820 10 67 1743
Covariate data set 1363
aBelow quantification limit or assay error
bTime for sampling and/or the time for the preceding dose could not be determined
6.2 Software tools
Four main tools were used in the thesis work; NONMEM, which is a
computer program for statistical analysis, was used to analyze the data
from the paclitaxel and imatinib studies, and to build population phar-
macokinetic models, MathModelica was used for model building that was
not directly based on data from the studies, and Mathematica and Maple
were used for further analysis of the models.
6.2.1 NONMEM - Papers I, II & III
NONMEM R© (Icon Development Solutions) is a program written in Fortran and
can be considered the gold standard software for nonlinear mixed effects modelling
in population pharmacokinetics/-dynamics. Although developed for implementation
and parameter estimation of models that are typically fitted to data from clinical stud-
ies involving several individuals, NONMEM can also be used as a general nonlinear
regression tool. It uses a subroutine called PRED (prediction) to obtain predicted
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values from regression analysis, and a specific subroutine called PREDPP (PRED
for population pharmacokinetics) can be used to estimate parameters in population
pharmacokinetic models. Several different estimation methods are available, where
the ones used for parameter estimation in population pharmacokinetic models of-
ten uses likelihood-based estimation, see the Methods chapter, Section 5.1, and the
NONMEM User’s Guides [4].
NONMEM VI was used in Papers I and II, while NONMEM 7 was used in Paper
III. For additional analyses and visualization of NONMEM results, the Xpose package
for the statistical programming language R, was used [44, 66]. For automatization of
NONMEM runs, Log-Likelihood Profiling (LLP), stepwise covariate modelling and
bootstrap analysis, Perl-speaks-NONMEM (PsN) was used [52].
6.2.2 MathModelica - Papers I & IV
MathModelica R© (MathCore Engineering AB) is a platform for the Modelica pro-
gramming language, which is developed for object-oriented modelling and simulation
of most dynamical systems (time-continuous, time-discrete or hybrid systems). The
combination of an object-oriented approach and an equation-based language offers the
possibility to create submodels of parts of a larger system and then connect these to
a complete model. Another feature is that the information flow between components
can be chosen to be either causal, i.e., the flow has a specified direction, or acausal, in
which case the flow has no specific direction. In addition to the Modelica language,
there is also an open-source Modelica Standard Library with predefined models, as
well as a number of additional open-source or commercial libraries [18, 19].
The MathModelica software includes an editor for graphical and textual represen-
tation of models, System Designer, and a simulation environment, Simulation Center
for performing model simulation experiments. Models and results from MathMod-
elica can be imported to Mathematica, enabling further analysis using Mathematica
functions.
MathModelica Professional 1.1 was used in combination with Mathematica 5.2 in
Paper I for the AUC-based sensitivity analysis.
MathModelica Professional 3.0 was used in combination with Mathematica 8 in
Paper IV for model building, constrained optimization and dynamic sensitivity anal-
ysis.
6.2.3 Mathematica - Papers I & IV
Mathematica R© (Wolfram Research, Inc.) is a general purpose system and computer
algebra system. Mainly, it uses a functional programming language, a property that
for instance implies very concise representations of functions. [32, 95, 98].
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Mathematica 5.2 was used in Paper I, were the function NIntegrate was used
in the sensitivity analysis to check variations of the area under curve (AUC) for
simulated plasma concentration.
Mathematica 8 was used in Paper IV, were the functions NDSolve and FindMinimum
were used for the constrained optimization problem.
6.2.4 Maple - Paper I
Maple R© (Maplesoft, Cybernet Systems Co., Ltd.) is a computer algebra system that
mainly uses a procedural programming language [32, 54].
Maple 10 was used for the structural identifiability analysis of the pharmacokinetic
models in Paper I. The analysis utilized a special package called observabilityTest,
see Methods chapter, Section 5.2, and Sedoglavic [76]. From a user perspective,
observabilityTest takes a model on state-space form as input and gives the tran-
scendence degree and the set of non-observable state-variables and parameters as
output.
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"All we have to decide is what to do with the time that is given to us."
Gandalf Grey, Lord of the Rings by J.R.R. Tolkien
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7 Results and Discussion
7.1 Paper I
Paper I aimed at comparing two published pharmacokinetic model struc-
tures for paclitaxel; the first one, denotedME (E for empirical), originally
based only on total paclitaxel concentrations, and a more mechanism-based
model structure, MM , originally based on both total and unbound pacli-
taxel concentrations, and also concentrations of the solubilizer Cremophor
EL. Specifically, the aim was to investigate if the more mechanistic model
structure, MM , could be used even if only total paclitaxel concentrations
were available. Results showed that MM had at least as good fit as ME,
if identifiability issues were properly handled. This means that total con-
centrations can be used in combination withMM to predict unbound con-
centrations, which are more relevant when investigating pharmacokinetic
variability.
7.1.1 Identifiablity analysis
Use of the local algebraic observability test (Methods chapter, Section 5.2) indicated
four parameters to be structurally non-identifiable for a reparametrized version of
MM :
D = {Vu1, BCrEL, Blin, KMB} (7.1)
where Vu1 is the volume of distribution of the central compartment, BCrEL is the
binding directly proportional to the Cremophor EL plasma concentration, Blin is the
linear binding to plasma components and KMB the unbound plasma concentration
at half of the maximum binding to plasma (Bmax).
In relation to the local algebraic observability test, it should be pointed out that
the approach assumes that the Cremophor EL plasma concentration, cCrEL(t), is an
additional input signal acting directly on the output of MM , i.e., the total pacli-
taxel concentration cMp(t). However, in the differential algebraic setting [69] used in
Sedoglavic [76] it is assumed that all inputs and their derivatives are independent.
In reality, clearly cCrEL(t) is dependent on the paclitaxel dosage, Dpac(t), because
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Cremophor EL is the solubilizer for paclitaxel. Therefore the Cremophor EL dose is:
DCrEL(t) = Dpac(t)/S (7.2)
where S is a scaling parameter with the dimension ml/µmol, since DCrEL(t) has the
dimension ml/h and Dpac(t) is in µmol/h. Because the observability test tests alge-
braic dependence, two cases representative for this dependence were tried. The first
case tested the observability for a completely independent input signal with respect to
Dpac(t) acting on cMp(t). The second case tested a fully dependent signal with respect
to Dpac(t), i.e., cCrEL(t) = Dpac(t). Because the two cases provided the same set of
non-identifiable parameters it was assumed that the degree of dependence between
cCrEL(t) and Dpac(t) was of less importance. The issue of input-output dependence
should also be seen in relation to other potentially problematic assumptions neces-
sary to use the observability test, such as the derivative of a step-like input signal, or
system noise [11].
7.1.2 Sensitivity analysis and parameter fixing
Sensitivity analysis based on the change in AUC over 48 hours identified KMB in (7.1)
to be least sensitive. Because preliminary runs in NONMEM indicated problems with
identifiability even after fixing KMB, it was assumed additional parameters had to be
fixed. Repeated NONMEM runs proved that fixing the parameters associated with
the second peripheral compartment, Qu3 and Vu3, resulted in a stable model. The
selection of these particular parameters was based on the comparison of estimates
associated with the two peripheral compartments from two previous studies as re-
ported by Henningsson et al. [35, 37], and presented in Table 7.1. Because Vu2 is the
Table 7.1: Estimates reported by Henningsson et al. [35, 37] for parameters associated with
the peripheral compartments
θM Henningsson et al. [35] Henningsson et al. [37]
Qu2 (l/h) 134 132
Vu2 (l) 856 3450
Qu3 (l/h) 213 151
Vu3 (l) 303 303
parameter that varies most between the two studies, the parameters of the second
peripheral compartment, Qu3 and Vu3 were fixed according to previous estimates [35].
Fixing the two parameters only resulted in an increase of +2.6 in the NONMEM
OFV, which is non-significant for p < 0.05.
An additional sensitivity analysis for parameters Qu2, Vu2, Qu3 and Vu3 showed
a small effect in general on the AUC over 48 hours, compared to the structurally
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non-identifiable parameters in (7.1). The results are presented in Table 7.2. Fixing
Qu3 and Vu3 instead of, e.g., Qu2 and Vu3, will correspond to entirely fixing the rate-
constant K31 = Qu3/Vu3 in a reparametrized model.
Table 7.2: Estimates and deviations from Henningsson et al. [35] for intercompartmental
clearances, Qu2, Qu3, volumes of distribution, Vu2, Vu3, and the structurally non-identifiable
parameters in (7.1), with the change in AUC over 48 hours
θM θˆ
H
M θˆ
H,−2SE
M θˆ
H,+2SE
M δ
H,−2SE (%) δH,+2SE (%)
Qu2 (l/h) 134 75 190 -0.27 0.13
Vu2 (l) 856 600 1100 0.37 -0.63
Qu3 (l/h) 213 120 310 -0.8 0.59
Vu3 (l) 303 180 430 0.24 -0.41
Vu1 (l) 229 150 310 -1.2 1.0
BCrEL 3.78 3.0 4.5 -12 11
Blin 7.59 5.8 9.4 -7.9 8.0
KMB (µmol/h) 0.000106 0.000015 0.00020 0.32 -0.24
7.1.3 Model comparison
Because the model structuresME andMM are not nested, the final modelsME(θˆE)
andMM(θˆM), was compared using the AIC, rather than the NONMEM OFV. The
AIC favoured the fit of the mechanism-based model, MM(θˆM), with ∆AIC = −31.
According to the rule of thumb (Methods chapter, Section 5.1.2), the difference may
be considered large enough to fully omit the empirical model. However, because only
variance elements were used in the Ω-matrices describing IIV, which is also the case in
the studies by Henningsson et al. [35] and Joerger et al. [43], and covariances between
random effects were not extensively studied, a more careful conclusion is preferred,
stating that the model structureMM is at least as good as andME. This conclusion
is also supported by the hold-out validation, which did not favour any of the two
models.
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7.2 Paper II
The purpose of Paper II was to develop a pharmacokinetic model for pa-
clitaxel and its metabolites, using data from a clinical study consisting of
thirty-three women on treatment for ovarian cancer. In particular, the
influence of the drug solubilizer Cremophor EL, and genetic mutations
(polymorphisms) in enzymes and transporter proteins on paclitaxel and
metabolites were investigated. Similar to paclitaxel, the concentration
curves of two of the metabolites were found to be influenced by the con-
centration of Cremophor EL. A small association was also found between
the elimination of the main metabolite and one of the transporter proteins.
7.2.1 Model for paclitaxel metabolites
The final model structure for unbound concentrations, predicted from observed total
concentrations, used a three-compartment model for paclitaxel, and one compartment
each for the three metabolites, according to Figure 7.1. Because only total concen-
trations of paclitaxel and metabolites were available, frequentist priors (Methods
chapter, Section 5.3) from the study by Henningsson et al. [35] were used to stabilize
parameter estimation. The relation between total concentration [pac]t and unbound
concentration [pac]u of paclitaxel, and concentration of Cremophor EL [CrEL] were
described according to the model developed by Henningsson et al. [35]:
[pac]t = [pac]u +Blin · [pac]u +BCrEL · [CrEL] · [pac]u + Bmax · [pac]u
Km + [pac]u
(7.3)
The model in (7.3) can be compared to the corresponding relations between total and
unbound concentrations of the hydroxy-metabolites 6α-hydroxypaclitaxel, [6αOH],
and p-3’-hydroxypaclitaxel, [p3OH], developed in this paper:
[6αOH]t = [6αOH]u +
B6αOH · [CrEL]HillCrEL
(CrEL50)HillCrEL + [CrEL]HillCrEL
· [6αOH]u +Bnsp,6αOH · [CrEL]
(7.4a)
[p3OH]t = [p3OH]u +
Bp3OH · [CrEL]HillCrEL
(CrEL50)HillCrEL + [CrEL]HillCrEL
· [p3OH]u +Bnsp,p3OH · [CrEL]
(7.4b)
where the Hill coefficient, HillCrEL, and CrEL50 are the same for the two metabolites.
CrEL50 is the Cremophor EL concentration at half of the maximal binding rates,
B6αOH, and Bp3OH, of the respective hydroxy-metabolites to potential Cremophor EL
micelles. Interindividual variability (IIV) was used for Blin, in (7.3), and for the Hill
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Figure 7.1: The compartment model for unbound concentrations.
coefficient, HillCrEL in (7.4). Of the two previous population pharmacokinetic models
based on both total and unbound paclitaxel concentrations, the first one by Hennings-
son et al. [35], from which the prior information used in this paper was acquired, did
not use any IIV in binding parameters. In the second model, Henningsson et al. [36]
used IIV in BCrEL in (7.3), but the reported coefficient of variation (CV) was only
14%, which can be compared to the CV of 101% for IIV in the parameter describing
plasma protein binding, Blin, in this work. Since the present model was only based
on total concentrations, used priors from a more heterogenous study [35], and used
simulated Cremophor EL concentrations from another population pharmacokinetic
model [38], it is likely that the large CV for IIV in Blin, is partly caused by differences
in models and data. This may also be the case for the relatively large CV of 41% for
IIV in HillCrEL.
The Hill equation has earlier been proposed by Piszkiewicz [64, 65] as a model for
micelle-catalyzed reactions, which give some support of its use as a binding model
in this work. The Hill coefficient in (7.4), HillCrEL, was estimated to 2.71, which is
in accordance with the range from approximately 1 to 6 of previously derived co-
efficients, for a number of combinations of detergents and substrates, as reported
by Piszkiewicz [65]. The non-specific term in (7.4) was clearly significant for both
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hydroxy-metabolites and seemed to be related to the Cremophor EL concentration.
However, it should be pointed out that the non-specific term is empirical in nature,
since it will make total metabolite concentrations depend explicitly on the concen-
tration of the solubilizer. The significance of different elements in the binding model
for hydoroxy-metabolites, as part of the final population pharmacokinetic model, is
presented in Table 7.3.
Table 7.3: Significance of the different elements in the binding model for hydroxy-
metabolites (7.4), as part of the final population pharmacokinetic model for paclitaxel and
its three metabolites
Change ∆OFVa ∆d.f.b
HillCrEL fixed to 1 with no IIV 173 -2
No non-specific term (nsp) for [p3OH]t in (7.4b) 215 -1
No non-specific term (nsp) for [6αOH]t in (7.4a) 114 -1
No IIV on HillCrEL 53 -1
No [CrEL] binding to non-specific terms (nsp) 21 0
Final model 0 0
Different CrEL50 for [6αOH]t and [p3OH]t -2 1
Different HillCrEL for [6αOH]t and [p3OH]t -19 2
[6αOH]t, total concentration 6α-hydroxypaclitaxel; [p3OH]t, total concentration p-3’-
hydroxypaclitaxel; [CrEL], concentration Cremophor EL
a ∆OFV is relative to the final model
b ∆d.f. is the difference in number of degrees of freedom
7.2.2 Covariate analysis
Stepwise covariate modelling was performed for genes ABCB1 (C3435T, G2677T/A),
CYP2C8 (*1B, *1C, *3, *4), CYP3A4 (*1B) and CYP3A5 (*3) in all clearance pa-
rameters (CL). None of the tested associations were significant for p < 0.01. All
associations found to be significant for p < 0.1, corresponding to a drop in OFV with
at least 2.71 units for one additional degree of freedom, were subject to further inves-
tigation using two alternative models. In addition to parameters already included in
the final model, both alternative models included IIV in V1 and V2, since these random
effects where part of the model developed by Henningsson et al. [35], from which pri-
ors were adopted. In Alternative model 2, IIV in Blin was excluded to exactly mimic
the parametrization in the original model [35]. In addition to the log-likelihood ratio
test using NONMEM OFV, an additional one-way ANOVA was performed using indi-
vidual predicted estimates (empirical Bayes estimates) from the FOCE. The influence
of the GM2677T/A variant on clearance of 6α-hydroxypaclitaxel, CL6αOH/fmpac, was
the only consistent association over all models and p < 0.1. For the final model,
individuals carrying the polymorphisms G/A (n = 3) or G/G (n = 5) showed a 30%
increase while individuals with polymorphism T/T (n = 8) showed a 27% decrease
38
relative the polymorphism G/T (n = 17). The effect estimates of G2677T/A were
however accompanied with a high uncertainty, and the 95% and 90% CIs (but not
the 80% CI) for the estimates included zero.
Since the current association has not been previously described, an additional
analysis was carried out for the final and alternative models, only using paclitaxel
concentrations. The purpose was to investigate whether the significant association
was transmitted to clearance of paclitaxel, CLpac, if no metabolite data was used. Re-
sults are presented in Table 7.4. In the absence of metabolite data, the GM2677T/A
variant turned out to be significantly associated to paclitaxel clearance over all mod-
els for p < 0.1. This association is also apparent for alternative model 1, but not for
the final model, when including metabolite data. It should be pointed out that IIV in
distribution volumes never turned out to be significant parameters during the model
building procedure, hence alternative model 1 was not used in the continued develop-
ment. This particular model also showed identifiability issues in some cases, resulting
in unreasonable high estimates. Overall, Table 7.4 may serve as an indication to why
associations may sometimes be significant and sometimes not. The conclusion would
be that several different combinations of data sets, models and significance tests may
stand a better chance of eliciting these kind of weak associations, than a single model
would.
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Table 7.4: Covariate testing of the ABCB1 variant GM2677T/A for three different models,
fitted to paclitaxel concentrations only, or both paclitaxel and metabolite concentrations
Model and parameter ∆OFVc p (∆OFV)d p (ANOVA)e
Model building based on paclitaxel concentrations only
Final model
CLpac 5.65 0.059 0.024
Alternative model 1a
CLpac 8.86 0.012 0.0071
Alternative model 2b
CLpac 7.14 0.028 0.010
Model building based on paclitaxel and metabolite concentrations
Final model
CLpac 2.23 0.33 0.21
CL6αOH/fmpac 7.38 0.025 0.012
Alternative model 1a
CLpac 5.14 0.077 0.033
CL6αOH/fmpac 4.79 0.091 0.048
Alternative model 2b
CLpac 3.42 0.18 0.073
CL6αOH/fmpac 5.86 0.054 0.033
a Alternative model 1 = Final model with IIVV1 and IIVV2
b Alternative model 2 = Alternative model 1 without IIVBlin
c For a model with fixed estimates instead of priors for paclitaxel parameters
d p-value based on the difference in OFV according to χ2(2)
e p-value based on one-way ANOVA of individual predicted estimates
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7.3 Paper III
The primary aim of Paper III was to develop a pharmacokinetic model for
imatinib, using data from a clinical study including fifty men and women
on long-term treatment for gastrointestinal stromal tumour. Specifically,
the model was intended to account for the possibility of decreasing plasma
concentrations over time. As a secondary aim, the effect of liver metastasis
on imatinib pharmacokinetics was investigated. Imatinib plasma concen-
trations were best fitted to a model that included a time delay between
drug intake and absorption. In addition, it was found that the model
should include mechanisms describing a substantial decrease in both the
amount of drug that is absorbed and the rate of this absorption. A small
effect was also found between the size of liver metastasis and drug clear-
ance.
7.3.1 Population pharmacokinetic model
Because the data set contained both rich sample occasions and in-between trough
samples, all dose events and observations in each individual data set were handled
in a time-consecutive manner, from start to end of study, instead of using an ap-
proach comprising interoccassion variability [48]. Steady-state levels were obtained
by assuming that dosing had occurred in 24-hour intervals for at least 10 days be-
fore a trough sample. Since imatinib was administrated orally, and no intravenous
drug administration data was available, the bioavailability (F ) was set to 1, meaning
that clearance (CL) and volume of distribution (V ) should be interpreted as the ap-
parent clearance (CL/F ) and volume of distribution (V/F ), respectively. Observed
plasma concentrations were log-transformed and residual errors were modelled using
an additive error. Interindividual variability (IIV) was modelled exponentially.
Plasma concentrations of imatinib were best fitted to a two compartment model,
with five transit compartments preceding the absorption compartment, according to
Figure 7.2. The transit compartments were included in a step-wise manner during
model development. The flexible way of determining an optimal non-integer number
for transit compartments by use of the Sterling approximation, as described by Savic
et al. [72], and adapted to handle multiple-dosing by Wilkins et al. [94], was considered
but not implemented, since preliminary runs indicated that relatively few transit
compartments could be used.
Previous population pharmacokinetic models for imatinib has mostly comprised
one-compartment models, with zero-order [15, 45, 56, 75] or first-order [62, 89, 93]
absorption and linear elimination. Previous studies using the population pharmacoki-
netic approach have in general used fewer imatinib observations (∼ 100 to 800) with
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Figure 7.2: The population pharmacokinetic model for imatinib, with five transit compart-
ments preceding the absorption, central and peripheral compartments.
fewer rich occasions and about the same number of subjects (∼ 10 to 70), than the
present study, which could account for its more elaborate model. Only the Phase III
trial study of imatinib in treatment of chronic myeloid leukaemia by Schmidli et al.
[75], surpasses in total number of observations (m = 1930) and number of subjects
(n = 371), although this study had considerably less samples per subject due to a
different sampling schedule with a shorter study period.
7.3.2 Time dependency
Adding time dependency on the bioavailability F and the absorption ka largely de-
creased the OFV compared to a model without time dependency, as can be seen in
Table 7.5, by comparing models no 1 and 7. Figure 7.3 describes the time depen-
dence in F and ka. Notably, the time dependency in F , could be replaced by an
almost equally good fit with a time dependent CL (Table 7.5, models no 6 and 7),
resulting in an increasing clearance with time, but this model was not robust and
highly sensitive to initial estimates. At least two previous studies using population
pharmacokinetic modelling have found evidence of time dependent imatinib pharma-
cokinetics; the Phase III trial study by Schmidli et al. [75] reported a decreased CL
from 14 to 10 l/h from Day 1 to Day 29, while Judson et al. [45] reported an increase
in CL with 33% after 12 months of treatment, which is in accordance with the current
study. Petain et al. [62] reported a decreased clearance (over the fraction metbolized)
for the metabolite CGP 74588, but not for imatinib, after 30 days compared to start
of treatment.
The importance of including time dependency in F and ka can be further visualized
by comparison of Visual Predictive Checks (VPC) [40]. The VPC in Figure 7.4
is based on the final model with time dependency in F and ka, but without any
covariates. This model has been fitted to all the rich occasions over all months and
also trough samples for subjects with no metastasis. On the other hand, the VPC
in Figure 7.5 is based on a model where the time dependency in F and ka has been
removed, and the model has been fitted only to the first sampling occasion in the
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Figure 7.3: Decrease in apparent bioavailability F (top) and absorption ka (bottom) over
time.
study at Day 1. Using the respective estimates, both models have then been simulated
against the data that were used in the final model, stratified on the different group of
months (Day 1, Months 1 to 3, Months 5 to 6, and Months 11 and above, according
to Table 6.2). In all sub-plots, black dots are the true observations, and the lines
are the 50th (solid), 5th (dashed lower) and 95th (dashed upper) percentiles of these
observations in each of the different time-intervals, comprising the 90% prediction
interval. The shaded areas are the 95% confidence intervals of the corresponding
percentiles for the simulated data (i.e., the predictions made by each model). In a
perfect model the dashed lines would go in the middle of the respective light-gray
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area and the solid line (the median) would go in the middle of the dark-gray area.
Except at Day 1, for the VPC in Figure 7.5, the lines are clearly below the respective
predicted confidence intervals. I.e., not using any time-effects will cause a large over-
prediction from the model.
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Figure 7.4: VPC for the final model (without the liver metastasis covariate).
To investigate compliance, pre-dose concentrations were compared to the maxi-
mum concentration for each rich occasion. Only one occasion in one subject where
found where non-compliance may be suspected, since the pre-dose concentration was
higher than all observations during the full course.
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Figure 7.5: VPC for a model where the time dependency in F and ka has been removed,
and where parameters have been estimated from the rich occasions at Day 1.
7.3.3 Covariate analysis
For sampling occasions with missing information on body weight (WT), data was
interpolated linearly between occasions, or extrapolated for WT missing at the start
or end of the study period, from the specific patient. For patients completely missing
data on body weight data was imputed by first taking the average within each patient
and then the median of the average values, and stratify on sex. WT on CL gave a
significant drop in OFV (Table 7.5, model no 8), but was omitted in the final model
because of too much data imputation.
Volume of liver metastasis (LIVM) ranged from 0.68 to 1800 cm3 (median 5.8 cm3)
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and the metastasis/liver volume ratio (LIVR), ranged from 0.042 to 61% (median
0.42%. Subjects not having liver metastasis were assigned LIVM = 0 and LIVR =
0 for all observations. The dichotomous covariate LIV was used to indicate whether
a subject had liver metastasis (LIV = 1) or not (LIV = 0). Imatinib observations
lacking information on LIVM and LIVR that belonged to subjects with metastasis
were excluded.
Only the size (LIVM) of liver metastasis (model no 11) prevailed as a significant
covariate (p < 0.01) when combined with other significant covariates (model no 19
and 20). The decrease in CL affected by LIVM could not be associated to the time
dependency (models no 17 and 18). The predicted decrease in CL implies that for
every 100 cm3 increase in metastasis volume CL is decreased by almost 4%. However,
for most subjects the metastasis will have very small effect on CL, considering the
median value of LIVM in the study group.
Table 7.5: Time and covariate effects on the imatinib population PK-model
No Time effect Covariate effect ∆OFV ∆d.f.c
1 - - 246.4 -3
2 - CL · (1− θcov · LIVM) 228.0 -2
3 CL - 168.7 -1
4 ka - 94.4 -1
5 F - 42.9 -1
6 CL, ka - 4.3 0
7a F , ka - 0 0
8 F , ka CL · (WTind/WTmedian)θcov -13.9 1
9 F , ka Vcentral · (WTind/WTmedian)θcov -0.3 1
10 F , ka CL · (1− θcov · LIV), LIV = 0/1 -0.4 1
11 F , ka CL · (1− θcov · LIVM) -21.8 1
12 F , ka Vcentral · (1− θcov · LIVM) -0.1 1
13 F , ka F · (1− θcov · LIVM) -7.1 1
14 F , ka CL · (1− θcov · LIVR) -11 1
15 F , ka Vcentral · (1− θcov · LIVR) -0.1 1
16 F , ka F · (1− θcov · LIVR) -1.7 1
17 F b, ka F ·
(
1− βF · (1− θcov · LIVM) · e−λ·TIME/24
)
0 1
18 F b, ka F ·
(
1− βF · e−λ·TIME/24·(1−θcov ·LIVM)
)
-0.1 1
19 F , ka CL · (1− θcov1 · LIVM), F · (1− θcov2 · LIVM) -21.8 2
20 F , ka CL · (1− θcov1 · LIVM) · (1− θcov2 · LIVR) -24.1 2
a Model no 7 is considered to be the reference model w.r.t. OFV and d.f.
b Covariate effect integrated in time effect for F
c ∆d.f. is the difference in number of degrees of freedom
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7.4 Paper IV
The aim of Paper IV was to develop a pharmacokinetic model, "bottom-
up". Instead of building a model based on patient data and try to explain
mechanisms on a cellular level ("top-down"), development started with
the cellular level, and the model was then scaled up to mimic the relevant
parts of a human body as far as possible. This way, mechanisms poten-
tially causing pharmacokinetic variability can be explicitly investigated.
According to the final model, the main metabolite of paclitaxel was rela-
tively largely affected also by small changes, while this was not the case
for paclitaxel itself.
7.4.1 Model development and constrained optimization
A semi-physiologically based pharmacokinetic model for paclitaxel and metabolites
was developed by using the intracellular pharmacokinetic model described by Kuh
et al. [49] and Jang et al. [41] as a starting point. The model was up-scaled and
extended to include three physiological compartments; systemic plasma, liver plasma
and liver tissue, and one output compartment, similar to the framework presented by
Sirianni and Pang [78]. Binding of paclitaxel and metabolites to plasma proteins and
Cremophor EL was described according to the relations between total and unbound
concentrations that have been used in population pharmacokinetic models [35, 38].
An extensive literature study was conducted to find reasonable parameter estimates
to use for the model structure.
Constrained optimization was used to adjust the parameters so that concentra-
tion ratios between metabolites and paclitaxel in systemic plasma, and amount ratios
between metabolites and paclitaxel in the output compartment were clinically reason-
able and in correspondence with Paper II and the findings by Walle et al. [91]. A sim-
ulation of the final model, based on a three-hour infusion and using the estimates from
the constrained optimization, is shown in Figure 7.6, with total concentrations (left)
and unbound concentrations (right) of paclitaxel and its metabolites. Total concentra-
tions are in the range of what has been clinically observed [14, 35, 36, 37, 43, 47]. No-
tably for paclitaxel, both total and unbound concentrations have two distinct phases,
with a very flat second phase before the of infusion (t = 3). In Figure 7.6, right panel,
it is also clear that the curve describing unbound concentrations for paclitaxel have
its maximum, not at the end of infusion but at the beginning of the flat phase. All
these characteristics are atypical in clinical studies [14, 35, 47], and are most likely a
result of the restricted compartmental space. Previously developed population phar-
macokinetic models of paclitaxel have used two or three compartments to describe
the distribution of the parent drug, but these cannot be used in the current model
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Figure 7.6: Simulations from the final model of total concentrations (left) and unbound con-
centrations (right) in systemic plasma of paclitaxel (solid), 6α-hydroxypaclitaxel (dashed),
p-3’-hydroxypaclitaxel (dotted) and 6α-, p-3’-dihydroxypaclitaxel (dash-dotted).
since their estimates for distribution volumes and compartmental flows depend on
unbound concentrations [35, 36, 37], or that they do not explicitly account for drug
binding [43, 47]. To test the hypothesis of a restricted compartmental space, a simula-
tion experiment using a ten times higher systemic plasma volume was performed, and
is shown in Figure 7.7, with total concentrations (left) and unbound concentrations
(left). By comparing Figures 7.6 and 7.7, it is apparent that while total paclitaxel
concentrations no longer have a visible break-point between the two phases, the curve
describing unbound concentrations have lost the initial peak, hence both curves show
a more similar appearance to the real clinical situation during the time for infusion
[35].
7.4.2 Dynamic sensitivity analysis
Influence of the transporters OATP and ABCB1, and the metabolizing enzymes
CYP2C8 and CYP3A4, on concentrations and amounts was investigated using dy-
namic sensitivity analysis [39, 90, 96]. According to the semi-physiologically based
pharmacokinetic model, metabolites were far more sensitive to changes in the metabolic
pathway than the parent drug. The predicted change in concentration from a 10%
decrease in different GEVmax at t = 3 hours, where the final model is using:
Vmax = GE
Vmax · Vmax, GEVmax = 1 (7.5)
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Figure 7.7: Simulation from a model using a ten times larger systemic plasma volume
than the final model, with total concentrations (left) and unbound concentrations (right) in
systemic plasma of paclitaxel (solid), 6α-hydroxypaclitaxel (dashed), p-3’-hydroxypaclitaxel
(dotted) and 6α-, p-3’-dihydroxypaclitaxel (dash-dotted).
is given by the upper two rows in Table 7.6. By using dynamic sensitivity analysis on
the alternative model with a ten times larger systemic plasma volume, the consistency
of the results can be tested, and are presented in the lower two rows of Table 7.6.
Results for the final model and the model with a ten times higher systemic plasma
Table 7.6: Change in total concentration of paclitaxel and 6α-hydroxypaclitaxel from a
10% decrease in different GEVmax in systemic plasma
Variablea GEVmaxOATP = 0.9 GE
Vmax
2C8 = 0.9 GE
Vmax
3A4 = 0.9 GE
Vmax
ABC = 0.9
x1(3) 2.3% 0.2% 0.1% 0.0%
x4(3) 5.0% -9.4% 6.7% 34.0%
x1(3, VSysP l×10) 1.8% 0.1% 0.0% 0.0%
x4(3, VSysP l×10) 2.3% -6.5% 4.3% 21.6%
a x1(3): total paclitaxel concentration in systemic plasma at t = 3 hours; x4(3): total
6α-hydroxypaclitaxel concentration in systemic plasma at t = 3 hours; x1(3, VSysP l×10):
total paclitaxel concentration in systemic plasma at t = 3 hours using a ten times larger
systemic plasma volume; x4(3, VSysP l×10): total 6α-hydroxypaclitaxel concentration in sys-
temic plasma at t = 3 hours using a ten times larger systemic plasma volume
volume are consistent, albeit the later model is in general less affected by the 10%
decrease. By comparing the peaks of total concentration of paclitaxel between the
two models, and their respective sensitivity for GEVmaxOATP , it is apparent in Figure 7.8,
that the peak ratio (at approximately three hours) for the sensitivity curves (right)
is larger than the peak ratio for the concentration curves (left). Notably, the model
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with the ten times larger systemic plasma volume shows a different shape also for the
sensitivity plot. In conclusion, comparing the change in AUC, in a similar way to
what is done in Paper I, instead of concentration at t = 3, may be a better measure
when testing consistency for the sensitivity analysis over different parameter values.
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Figure 7.8: Total paclitaxel concentrations (left) and sensitivity in GEVmax for OATP
(right), for the final model (solid) and the model with a ten times larger systemic plasma
volume (dashed).
Overall, the results from the dynamic sensitivity analysis are in correspondence
with observations from clinical studies. Of the two large large population pharma-
cokinetic studies looking at potential associations between genetic polymorphisms
and paclitaxel kinetics, only Bergmann et al. [6] reported a significant finding in a
population of 93 women, in which carriers of CYP2C8*3 had 11% lower clearance
than non-carriers. Henningsson et al. [37] did not find any significant associations of
CYP2C8, CYP3A4, CYP3A5, or ABCB1 in a much more heterogenous population
of 97 men and women. While none of the larger studies investigated associations be-
tween polymorphisms and metabolites, the semi-physiologically based model supports
the results from Paper II, where polymorphisms for the ABCB1 transporter showed
a significant association to clearance of 6α-hydroxypaclitaxel. From Table 7.6 it is
evident that the influence of ABCB1 on 6α-hydroxypaclitaxel is the most sensitive
pathway according to the model. This could mean that this particular association
may be the most apparent one in a clinical study.
50
8 Conclusions
Specific conclusions for the work in this thesis can be summarized as follows:
• Plasma concentrations of total paclitaxel can be used in pharmacokinetic mod-
elling to predict the relation between total and unbound drug. This is important
since only unbound drug is subject to membrane-protein transport and enzy-
matic metabolism.
• The solubilizer Cremophor EL seems to have a strong effect on the kinetics
of paclitaxel hydroxymetabolites. Clearance of predicted unbound concentra-
tions of the main metabolite 6α-hydroxypaclitaxel indicates an association with
genetic polymorphisms in the ABCB1 gene.
• The pharmacokinetics for long-term treatment of gastrointestinal stromal tu-
mour with imatinib is best described using a model with absorption delay and
time dependent apparent bioavailability and absorption rate. Patients with
considerable liver metastasis may have reduced drug clearance.
• The developed semi-physiologically based pharmacokinetic model for paclitaxel
predicts systemic plasma concentrations of the metabolite 6α-hydroxypaclitaxel
to be sensitive to changes in ABCB1 transport capacity.
Considering the overall aim of the thesis in relation to the conclusions:
Even for studies relatively rich in samples and subjects, geno- and phenotype co-
variates have little effect on the model fit compared to effects from drug binding
or treatment duration. Hence, in order to individualize drug therapy, modelling may
have to be moved to a lower level of detail, while keeping the perspective on the whole
human body, as proposed by for instance Aarons [1]. Already, it may in general be
difficult to investigate all important properties of a specific system due to limitations
in data. Moving to an even more detailed level would therefore increase the need for
methods that can combine physiologically-based models with molecular models, and
previously developed models with new data.
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Populärvetenskaplig sammanfattning
Farmakokinetisk variabilitet i en population kan sägas vara variationen mellan in-
dividernas blodplasmakoncentrationer av ett visst läkemedel. Denna variation kan
till exempel orsakas av skillnader i gener som kodar för transportproteiner och en-
zymer, mängden kroppsfett, ålder, kön, diet eller patientens sjukdomstillstånd. För
cancerläkemedel kan kombinationen av en hög variabilitet och ett så kallad smalt
terapeutiskt fönster, d.v.s. skillnaden mellan en ineffektiv och en skadlig dos är liten,
orsaka farliga biverkningar med ytterligare lidande som följd för den redan drabbade
patienten och med höga kostnader för samhället.
Arbetet i denna avhandling syftar till att utforska möjligheterna till att individu-
alisera behandling av två specifika cancerläkemedel, paklitaxel och imatinib, genom
att utveckla matematiska modeller för att undersöka deras farmakokinetiska vari-
abilitet.
Delarbete I syftade till att jämföra två publicerade farmakokinetiska modeller för
paklitaxel. Den första modellen baseras endast på totala paklitaxelkoncentrationer,
medan den andra som är en mer mekanistiskt trolig modell baseras normalt på både
totala och obundna paklitaxelkoncentrationer, och även på koncentrationerna av lös-
ningsmedlet Cremophor EL. Mer specifikt var syftet att undersöka om den mekanis-
tiska modellen kan användas även om bara totala paklitaxelkoncentrationer finns till-
gängliga. Resultaten visade att så var fallet och att det därmed är möjligt att utifrån
totala koncentrationer beskriva hur obundna koncentrationer rör sig i kroppen. Detta
är viktigt eftersom endast obundet läkemedel kan transporteras obehindrat eller bry-
tas ned i levern, och därmed kan sägas vara närmre kopplat till den farmakokinetiska
variabiliteten.
Delarbete II syftade till att utveckla en farmakokinetisk modell för paklitaxel och
dess metaboliter med hjälp av data från en klinisk studie bestående av trettiotre
kvinnor som fick cellgiftsbehandling för äggstockscancer. Delarbetet visade att lik-
som läkemedlet själv påverkas troligen också två av läkemedelsmetaboliterna till hög
grad av lösningsmedlet Cremophor EL. Det visade sig också att den huvudsakliga
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metaboliten verkar påverkas av vissa genetiska mutationer i ett så kallad transport-
protein. Båda resultaten kan vara viktiga om det i framtiden visar sig att även
metaboliterna kan orsaka biverkningar.
Delarbete III syftade till att utveckla en farmakokinetisk modell för imatinib genom
att använda data från en klinisk studie med femtio män och kvinnor som fick långtids-
behandling för gastrointestinal stromacellstumör. Målet var att undersöka om det
fanns en trend till minskade plasmakoncentrationer under behandlingstiden, samt
att undersöka om läkemedelsnedbrytningen påverkades av om cancern hade spritt
sig till levern (levermetastaser). Enligt modellen visade det sig att både den mängd
läkemedel som absorberas av kroppen och den hastighet med vilket läkemedlet ab-
sorberas minskade väsentligt under behandlingstiden. Det visade sig också att pa-
tienter med väldigt stora levermetastaser hade minskad nedbrytning av läkemedlet.
Delarbete IV syftade till att utveckla en fysiologisk farmakokinetisk modell genom
att utgå från en matematisk modell på cellnivå och sedan skala upp denna, istället
för att som i Delarbeten I och II bygga en modell baserad på patientdata. På detta
sätt kan de mekanismer som styr transport och nedbrytning av läkemedlet studeras
noggrant genom datorsimuleringar. Enligt den slutliga modellen påverkades pakli-
taxel nästan inte alls av variationer under simuleringarna. Däremot påverkades den
huvudsakliga metaboliten av variationer i det transportprotein som även framkom i
Delarbete II.
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